[(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] undecanoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: [(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] undecanoate
• 化学式: C90H144O9
• 分子量: 1370.1
• InChiKey: MXLHRLCPZPXZMC-YQQLCGTHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  23.88
• 重原子数：
  99
• 可旋转键数：
  33
• 环数：
  12.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  130
• 氢给体数：
  0
• 氢受体数：
  9

文献信息

• EMULSION FORMULATIONS
  申请人：Differential Drug Development Associates LLC

  公开号：EP2968137A1

  公开（公告）日：2016-01-20
• [EN] EMULSION FORMULATIONS<br/>[FR] FORMULATIONS D'ÉMULSION
  申请人：DIFFERENTIAL DRUG DEV ASSOCIATES LLC

  公开号：WO2014143127A1

  公开（公告）日：2014-09-18

  A SEDDS or SMEDDS or SNEDDS formulation for drug delivery of a lipophilic therapeutic agent, providing enhanced modulation of solubility, stability, absorption, metabolism, and/or pharmacokinetic profile of the therapeutic agent by formulation with phytosterols and/or phytosterol esters, a hydrophobic surfactant, a hydrophilic surfactant, and optionally, one or more solubilizers and/or one or more digestible oils, resulting in higher bioavailability of the therapeutic agent administered to a subject in need of such therapeutic agent. Also described are pharmaceutical compositions containing the formulations and methods of making and methods of using the formulations and pharmaceutical compositions. Formulations of the disclosure can be constituted to minimize the synthesis of dihydrotestosterone when the therapeutic agent includes testosterone or testosterone esters.